logo
  • Home
  • Applications
    • Indications
  • Business
  • Technology
  • Investors
    • Investors Overview
    • Results and Presentations
    • Share Price Information
    • Regulatory News
    • Board & Governance
    • Key Corporate Documents
    • AIM Rule 26
    • Email Alerts
    • Investor Contacts
  • News
  • About Us
    • History
    • Board of Directors
    • Management Team
    • Scientific Advisory Panel
    • Values
    • Careers
  • Contact Us

Month: October 2015

Frost & Sullivan awards OBD the Best Innovative Technology 2015, for its Biomarker Discovery Platform in Monaco.

Frost & Sullivan award press release

 

by Catia Gaspar

The Stratification Medicine Grant Project initiates collection of first blood samples from ALS patients at the Nuffield Department of Clinical Neuroscience (OBD - Chronos Therapeutics - University of Oxford).

by Catia Gaspar

Dr. Aroul Ramadass gives a talk on EpiSwitch™ technology translation at the Medical Device Conference "See Manufactures in Action: Rapid Transformation", Berlin, Germany.

by Catia Gaspar

A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.

Melanoma Research, 25(5):406-11, 2015

by oxfordbiodynamics

Recent Posts

  • Ectopic gene deregulations and chromosome conformations: integrating novel molecular testing into clinical applications, from leukemias to gliomas
  • Oxford BioDynamics strengthens commercial focus with two Board appointments
  • Glen Ferguson appointed as Senior Vice President, USA
  • Oxford BioDynamics joins Imperial College London in a trial evaluating novel methods of screening for prostate cancer
  • Generative modeling of multi-mapping reads with mHi-C advances analysis of Hi-C studies.

Archives

  • April 2019
  • March 2019
  • January 2019
  • November 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • July 2015
  • June 2015
  • April 2015
  • March 2015
  • January 2015
  • December 2014
  • October 2014
  • September 2014
  • August 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • April 2012
  • March 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • August 2011
  • July 2011
  • June 2011
  • April 2011
  • March 2011
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • February 2010
  • January 2010
  • December 2009
  • September 2009
  • August 2009
  • July 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • October 2008
  • September 2008
  • June 2008
  • May 2008
  • January 2008
  • December 2007
  • October 2007
  • September 2007
  • June 2007
  • April 2007
  • February 2007
  • February 2006

Categories

  • Episwitch Publication
  • Events
  • Milestones
  • People
  • Publications
  • Uncategorized

Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

Terms of Use 
Site Map

Privacy Policy
Cookies Policy

Regulated and Licensed by Human Tissue Authority
License No. 12571

© 2002-2018 Oxford Biodynamics Plc

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this.OkRead more